Devyser lämnar ett starkt helår bakom sig och står välrustade inför ett högintressant 2023.
Q4: 4% sales growth y-o-y, but EBITA almost halved PION Group reported Q4 sales of SEK 532m (512m), ...
Redeye concludes that Q4 was stronger than expected, both on revenues and much above on EBIT.
Redeye will likely raise its Base Case and forecasts following a strong Q4, in line with the prelimi...
Redeye provides an update on Thunderful Group following its Q4 2022 report which was released on Feb...
Redeye comments on W5’s Q4-results where revenue came in stronger than expected while profit was bel...
Calliditas recorded Q4 Tarpeyo sales of SEK 169m which is slightly below our and the markets expecta...
ARR was EUR18.4m in Q4 2022, growing 19% YoY and 4.
Efter stora förändringar av både värdena på portföljinnehaven såväl som själva portföljen lägger Nor...
Vow published its H2 22 report this morning, with the numbers securing record FY revenue (landbased ...
Redeye updates its estimates following Freemelt’s Q4 report, which came in lower than expected due t...
Another impressive quarter in Norway Denmark is also gaining momentum Growth initiatives hurt profit...
Redeye comments on BioInvent's Q4 report. The most significant development in the period is the init...
Redeye is excited to hear that Impact Coatings and Plug Power have signed an LoI for a supply or fra...
Atria ended a volatile 2022 with a strong Q4 that came in well above our expectations on adjusted EB...
Raketech reported solid Q4 results, with revenue of EUR 17.
Redeye returns with a research update following the Q4 report and recent progress in the company.
Redeye comments on Cereno Scientific’s Q4 2022 report.
12% (pre-Q4) dilutive EPS impact, ND from EUR 30m to 15m Alleviates gearing concerns until earnings ...
AcouSort publicerade den 22 februari 2023 bolagets delårsrapport för Q4-22.
